Search Results - "Pohlman, Brad L."

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma by WITZIG, Thomas E, GORDON, Leo I, GRILLO-LOPEZ, Antonio J, MULTANI, Pratik, WHITE, Christine A, CABANILLAS, Fernando, CZUCZMAN, Myron S, EMMANOUILIDES, Christos, JOYCE, Robin, POHLMAN, Brad L, BARTLETT, Nancy L, WISEMAN, Gregory A, PADRE, Norman

“…Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory…”
Get full text

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era by Starr, Adam G, Caimi, Paolo F, Fu, PingFu, Massoud, Mira R, Meyerson, Howard, Hsi, Eric D, Mansur, David B, Cherian, Sheen, Cooper, Brenda W, De Lima, Marcos J G, Lazarus, Hillard M, Gerson, Stanton L, Jagadeesh, Deepa, Smith, Mitchell R, Dean, Robert M, Pohlman, Brad L, Hill, Brian T, William, Basem M

“…Splenic marginal zone lymphoma (SMZL) is a rare non-Hodgkin lymphoma. We sought to identify prognostic factors and define outcomes in a cohort of 64 patients…”
Get more information

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma by FORERO-TORRES, Andres, DE VOS, Sven, SMITH, Mitchell R, LINK, Brian K, WOOLDRIDGE, James E, GANJOO, Kristen N, POHLMAN, Brad L, PASHKEVICH, Maksim, CRONIER, Damien M, DANG, Nam H, CARPENTER, Susan P, ALLAN, Barrett W, NELSON, James G, SLAPAK, Christopher A

“…AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC)…”
Get full text

Is rituximab sub‐optimally dosed in indolent B cell lymphoma? by Sawalha, Yazeed, Rouphail, Basel, Jia, Xuefei, Dean, Robert M., Hill, Brian T., Jagadeesh, Deepa, Pohlman, Brad L., Smith, Mitchell R.

“…Rituximab pharmacokinetics are affected by gender, age and weight and can affect outcomes in aggressive B cell lymphoma. Less is known about the…”
Get full text

Dual institution experience of nodal marginal zone lymphoma reveals excellent long‐term outcomes in the rituximab era by Starr, Adam G., Caimi, Paolo F., Fu, PingFu, Massoud, Mira R., Meyerson, Howard, Hsi, Eric D., Mansur, David B., Cherian, Sheen, Cooper, Brenda W., De Lima, Marcos J. G., Lazarus, Hillard M., Gerson, Stanton L., Jagadeesh, Deepa, Smith, Mitchell R., Dean, Robert M., Pohlman, Brad L., Hill, Brian T., William, Basem M.

“…Summary Nodal marginal zone lymphoma (NMZL) is a rare non‐Hodgkin lymphoma that arises from mature B‐cells. We delineate outcomes, prognostic factors and…”
Get full text

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes by Starr, Adam G., Caimi, Paolo F., Fu, PingFu, Massoud, Mira R., Meyerson, Howard, Hsi, Eric D., Mansur, David B., Cherian, Sheen, Singh, Arun D., Cooper, Brenda W., De Lima, Marcos J.G., Lazarus, Hillard M., Gerson, Stanton L., Jagadeesh, Deepa, Smith, Mitchell R., Dean, Robert M., Pohlman, Brad L., Hill, Brian T., William, Basem M.

“…Summary Extranodal marginal zone lymphoma (EMZL) is a B‐cell lymphoma arising from mucosa‐associated lymphoid tissue (MALT). The disease characteristics,…”
Get full text

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma by Ganjoo, Kristen N., de Vos, Sven, Pohlman, Brad L., Flinn, Ian W., Forero-Torres, Andres, Enas, Nathan H., Cronier, Damien M., Dang, Nam H., Foon, Kenneth A., Carpenter, Susan P., Slapak, Christopher A., Link, Brian K., Smith, Mitchell R., Mapara, Markus Y., Wooldridge, James E.

“…Abstract This phase 2 study assessed the safety and efficacy of ocaratuzumab, a humanized anti-CD20 monoclonal antibody. Fifty patients with previously treated…”
Get full text

High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma by Smith, Stephen D., Bolwell, Brian J., Advani, Anjali S., Andresen, Steven W., Chan, Josephine L., Dean, Robert M., Hsi, Eric D., Kalaycio, Matt E., Pohlman, Brad L., Rybicki, Lisa A., Sweetenham, John W.

“…Transformed lymphoma (TL) is historically associated with a poor prognosis, though autologous stem cell transplantation (ASCT) has been applied successfully…”
Get full text

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2 by Allen, Joshua M., Ruano Mendez, Ana Lucia, Rybicki, Lisa A., Jagadeesh, Deepa, Dean, Robert M., Pohlman, Brad L., Smith, Mitchell Reed, Hsi, Eric D., Hill, Brian Thomas

“…Abstract only…”
Get full text

Is rituximab sub-optimally dosed in indolent B cell lymphoma? by Sawalha, Yazeed, Rouphail, Basel, Jia, Xuefei, Dean, Robert M., Hill, Brian Thomas, Jagadeesh, Deepa, Pohlman, Brad L., Elson, Paul, Smith, Mitchell Reed

“…Abstract only…”
Get full text

Long term outcomes of hairy cell leukemia patients treated with first and subsequent line with purine analog: The Cleveland Clinic experience by Madanat, Yazan, Rybicki, Lisa A., Jagadeesh, Deepa, Dean, Robert M., Pohlman, Brad L., Kalaycio, Matt E., Smith, Mitchell Reed, Hill, Brian Thomas

“…Abstract only…”
Get full text

Outcomes and prognostic factors in marginal zone lymphoma: Case comprehensive cancer center cumulative experience of 358 cases by Starr, Adam, Fu, PingFu, Caimi, Paolo Fabrizio, Campagnaro, Erica Leigh, Cooper, Brenda W., De Lima, Marcos J.G., Lazarus, Hillard M., Gerson, Stanton L., Meyerson, Howard, Jagadeesh, Deepa, Smith, Mitchell Reed, Dean, Robert M., Pohlman, Brad L., Hill, Brian Thomas, William, Basem M.

“…Abstract only…”
Get full text

Association of prior rituximab exposure among patients undergoing autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma with inferior outcomes in males compared with females by Lazaryan, Aleksandr, Copelan, Edward Alan, Bejanyan, Nelli, Dean, Robert M., Sobecks, Ronald M., Hill, Brian Thomas, Pohlman, Brad L., Kalaycio, Matt E., Bolwell, Brian James, Sweetenham, John W.

“…Abstract only 8055 Background: The combination of rituximab with CHOP remains the standard upfront therapy of patients (pts) with advanced diffuse large B-cell…”
Get full text

Defining quality and value in a prospective study of an emergency department (ED) febrile neutropenia pathway (FNP) by Keng, Michael Kenneth, Thallner, Elaine A., Elson, Paul, Ajon, Christine, Sekeres, Jennifer, Wenzell, Candice M., Gallagher, Erika M., Weber, Catherine M., Earl, Marc A., Mukherjee, Sudipto, Seastone, David James, Pohlman, Brad L., Cober, Eric, Rodgers, Beth, Foster, Virginia B., Yuhas, Joy, Kalaycio, Matt E., Bolwell, Brian James, Sekeres, Mikkael A.

“…Abstract only…”
Get full text

Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab by Wayne, Jennifer L., Ganjoo, Kristen N., Pohlman, Brad L., De Vos, Sven, Flinn, Ian W., Dang, Nam H., Mapara, Markus Y., Smith, Mitchell R., O'Reilly, Adrienne M., Marulappa, Shashidhara Y., Jain, Vinay Kumar

“…Abstract only 8081 Background: Ocaratzumab, previously known as AME-133v, is a humanized next-generation anti-CD20 monoclonal antibody. It has been optimized…”
Get full text

Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma by Picozzi, V J, Pohlman, B L, Morrison, V A, Lawless, G D, Lee, M W, Kerr, R O, Ford, J M, Delgado, D J, Fridman, M, Carter, W B

“…Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy…”
Get more information